Apoptotic mesenchymal stromal cells support osteoclastogenesis while inhibiting multinucleated giant cells formation in vitro.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 06 2021
Historique:
received: 29 03 2021
accepted: 24 05 2021
entrez: 10 6 2021
pubmed: 11 6 2021
medline: 3 11 2021
Statut: epublish

Résumé

In bone regeneration induced by the combination of mesenchymal stromal cells (MSCs) and calcium-phosphate (CaP) materials, osteoclasts emerge as a pivotal cell linking inflammation and bone formation. Favorable outcomes are observed despite short-term engraftments of implanted MSCs, highlighting their major paracrine function and the possible implication of cell death in modulating their secretions. In this work, we focused on the communication from MSCs towards osteoclasts-like cells in vitro. MSCs seeded on a CaP biomaterial or undergoing induced apoptosis produced a conditioned media favoring the development of osteoclasts from human CD14+ monocytes. On the contrary, MSCs' apoptotic secretion inhibited the development of inflammatory multinucleated giant cells formed after IL-4 stimulation. Components of MSCs' secretome before and after apoptotic stress were compared using mass spectrometry-based quantitative proteomics and a complementary immunoassay for major cytokines. CXCR-1 and CXCR-2 ligands, primarily IL-8/CXCL-8 but also the growth-regulated proteins CXCL-1, -2 or -3, were suggested as the major players of MSCs' pro-osteoclastic effect. These findings support the hypothesis that osteoclasts are key players in bone regeneration and suggest that apoptosis plays an important role in MSCs' effectiveness.

Identifiants

pubmed: 34108508
doi: 10.1038/s41598-021-91258-4
pii: 10.1038/s41598-021-91258-4
pmc: PMC8190145
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12144

Références

Front Bioeng Biotechnol. 2019 Nov 27;7:352
pubmed: 31828066
Front Immunol. 2019 Apr 02;10:663
pubmed: 31001270
J Biol Chem. 2019 Jul 19;294(29):11240-11247
pubmed: 31167789
PLoS One. 2012;7(11):e48648
pubmed: 23144918
Stem Cells. 2013 Mar;31(3):526-35
pubmed: 23225732
Biomaterials. 2019 Mar;196:100-108
pubmed: 29598897
Stem Cells Transl Med. 2015 Jul;4(7):809-21
pubmed: 25979862
Arthritis Rheum. 2011 Jun;63(6):1658-67
pubmed: 21360521
Regen Med. 2017 Oct;12(7):803-813
pubmed: 29115906
Biomaterials. 2014 Dec;35(36):9660-7
pubmed: 25176068
Cytotherapy. 2019 Apr;21(4):468-482
pubmed: 30926359
Nature. 2020 Apr;580(7801):130-135
pubmed: 32238926
Bone. 2003 Jul;33(1):28-37
pubmed: 12919697
Sci Rep. 2018 May 16;8(1):7716
pubmed: 29769543
Cell Physiol Biochem. 2018;48(1):361-370
pubmed: 30016780
J Oral Sci. 2019 Mar 28;61(1):30-35
pubmed: 30541990
Theranostics. 2020 May 22;10(15):6825-6838
pubmed: 32550906
Biomaterials. 2006 Sep;27(25):4419-27
pubmed: 16690121
Injury. 2020 Apr;51 Suppl 1:S63-S73
pubmed: 32139130
Clin Exp Immunol. 2021 Feb;203(2):194-208
pubmed: 33010041
Tissue Eng Part A. 2014 Oct;20(19-20):2737-45
pubmed: 24701989
Endocrinology. 1999 Aug;140(8):3736-43
pubmed: 10433234
Bioinformatics. 2017 Jan 1;33(1):135-136
pubmed: 27605098
Biol Open. 2014 Jul 25;3(8):767-76
pubmed: 25063197
Sci Signal. 2010 Oct 26;3(145):re8
pubmed: 20978240
Proteomics. 2013 Aug;13(16):2419-23
pubmed: 23744604
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
J Cell Biochem. 2013 Aug;114(8):1772-8
pubmed: 23444125
Tissue Eng Part A. 2010 Feb;16(2):489-99
pubmed: 19712045
Cell Stem Cell. 2008 Sep 11;3(3):301-13
pubmed: 18786417
Tissue Eng Part A. 2012 Oct;18(19-20):2084-94
pubmed: 22578283
Annu Rev Physiol. 2020 Feb 10;82:507-529
pubmed: 31553686
Acta Biomater. 2016 Dec;46:15-28
pubmed: 27667014
Cytokine Growth Factor Rev. 2009 Feb;20(1):19-28
pubmed: 19038573
Front Bioeng Biotechnol. 2020 Jun 24;8:641
pubmed: 32671040
Nat Protoc. 2019 Mar;14(3):703-721
pubmed: 30804569
Clin Exp Metastasis. 2015 Apr;32(4):353-68
pubmed: 25802102
Stem Cells Transl Med. 2017 Dec;6(12):2160-2172
pubmed: 29052365
Biofactors. 2017 Sep 10;43(5):633-644
pubmed: 28718997
Pharmacol Res. 2000 Oct;42(4):373-81
pubmed: 10987998
Tissue Eng Part A. 2009 Aug;15(8):2203-12
pubmed: 19265473
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141887
Stem Cell Res Ther. 2014 Oct 13;5(5):114
pubmed: 25311054
Biomaterials. 2019 Mar;196:80-89
pubmed: 29329642
Bioinformatics. 2020 May 1;36(10):3148-3155
pubmed: 32096818
Stem Cell Res Ther. 2018 Aug 9;9(1):213
pubmed: 30092840
Stem Cells Int. 2018 Feb 22;2018:6025918
pubmed: 29535772
Front Immunol. 2019 Jun 04;10:1191
pubmed: 31214172
Acta Biomater. 2013 Sep;9(9):8037-45
pubmed: 23791671
Clin Oral Investig. 2017 Jul;21(6):1979-1988
pubmed: 27796573
Front Immunol. 2018 Dec 04;9:2837
pubmed: 30564236
Biomaterials. 2013 Dec;34(38):9917-25
pubmed: 24054499

Auteurs

Paul Humbert (P)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France. paul.humbert@univ-nantes.fr.

Meadhbh Á Brennan (MÁ)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.
Regenerative Medicine Institute, School of Medicine, and Bioengineering Department, School of Engineering, National University of Ireland, Galway, H91 TK33, Ireland.

Julien De Lima (J)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Régis Brion (R)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.
CHU Nantes, 44000, Nantes, France.

Annie Adrait (A)

Université Grenoble Alpes, CEA, INSERM, IRIG, BGE, 38000, Grenoble, France.

Céline Charrier (C)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Bénédicte Brulin (B)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Valérie Trichet (V)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Yohann Couté (Y)

Université Grenoble Alpes, CEA, INSERM, IRIG, BGE, 38000, Grenoble, France.

Frédéric Blanchard (F)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Pierre Layrolle (P)

UMR 1238, Phy-OS, Bone Sarcoma and Remodeling of Calcified Tissues, School of Medicine, University of Nantes, INSERM, 44000, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH